Efficiency and safety of transfer of type 2 diabetes patients inadequately controlled on metformin alone to combined therapy with metformin and diabeton MB
https://doi.org/10.14341/2072-0351-5708
Abstract
Aim.
To evaluate efficiency and tolerability of diabeton MB/metformin combination in patients failing to achieve optimal glycemic control when onmetformin monotherapy and prove advantages of this combination over combined low-dose therapy with glibenclamide and metformin.
Materials and methods.
The study included 464 patients with type 2 diabetes mellitus who poorly responded to metformin monotherapy. It was supplementedby diabeton MB. Efficiency and tolerability of combined treatment was evaluated from dynamics of glycemia and frequency of side-effects.40 patients were included in detailed comparative assessment (laboratory and instrumental, CGMS) of this monotherapy and fixed low-dose combinationof glibenclamide with metformin.
Results.
Results of comparison show that diabeton MB/metformin combination ensured most optimal glycemic control with a minimal risk of side effects.
Conclusion.
Diabeton MB/metformin combination is convenient, efficient and safe.
To evaluate efficiency and tolerability of diabeton MB/metformin combination in patients failing to achieve optimal glycemic control when onmetformin monotherapy and prove advantages of this combination over combined low-dose therapy with glibenclamide and metformin.
Materials and methods.
The study included 464 patients with type 2 diabetes mellitus who poorly responded to metformin monotherapy. It was supplementedby diabeton MB. Efficiency and tolerability of combined treatment was evaluated from dynamics of glycemia and frequency of side-effects.40 patients were included in detailed comparative assessment (laboratory and instrumental, CGMS) of this monotherapy and fixed low-dose combinationof glibenclamide with metformin.
Results.
Results of comparison show that diabeton MB/metformin combination ensured most optimal glycemic control with a minimal risk of side effects.
Conclusion.
Diabeton MB/metformin combination is convenient, efficient and safe.
About the Authors
Alexander Sergeevich Ametov
Russian Medical Academy of Advanced Studies, Moscow
Lyudmila Nikolaevna Bogdanova
Russian Medical Academy of Advanced Studies, Moscow
References
1. Дедов И.И., Фадеев В.В. Введение в диабетологию. - М.: Берг. - 1998. - 200 с.
2. UKPDS Group. Glycaemic control with diet, sulfonnylureas, metformine, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPD 49) // JAMA. - 1999. - 281. - Р. 2005-2012.
3. Анциферов М.Б. Результаты UKPDS и их значение в совершенствовании специализированной помощи больным диабетом // Сахарный диабет. - 1999. - № 4. - С. 23-27.
4. Балаболкин М.И., Петунина Н.А., Тельнова М.Э., Клебанова Е.М., Антонова К.В. Роль инсулиновой терапии в компенсации сахарного диабета // РМЖ. - 2007. - Т. 15, № 27. - С. 2072-2077.
5. The ADVANCE Collaborative Group // N. Engl. J. Med. - 2008. - 358 - Р. 2560-2572.
6. Смирнова О.М. Преимущества комбинированной терапии в лечении сахарного диабета 2 типа // Фарматека. - 2008. - № 3. - С. 48-51.
Review
For citations:
Ametov A.S., Bogdanova L.N. Efficiency and safety of transfer of type 2 diabetes patients inadequately controlled on metformin alone to combined therapy with metformin and diabeton MB. Diabetes mellitus. 2009;12(4):68-71. (In Russ.) https://doi.org/10.14341/2072-0351-5708
Views:
22275
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
